These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26474763)

  • 1. Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.
    Ríos Quiroz A; Lamerz J; Da Cunha T; Boillon A; Adler M; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV
    Pharm Res; 2016 Feb; 33(2):450-61. PubMed ID: 26474763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.
    Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML
    J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
    Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods To Determine the Silicone Oil Layer Thickness in Sprayed-On Siliconized Syringes.
    Loosli V; Germershaus O; Steinberg H; Dreher S; Grauschopf U; Funke S
    PDA J Pharm Sci Technol; 2018; 72(3):278-297. PubMed ID: 29343617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregation and Particle Formation of Therapeutic Proteins in Contact With a Novel Fluoropolymer Surface Versus Siliconized Surfaces: Effects of Agitation in Vials and in Prefilled Syringes.
    Teska BM; Brake JM; Tronto GS; Carpenter JF
    J Pharm Sci; 2016 Jul; 105(7):2053-65. PubMed ID: 27233685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals.
    Khodabandehloo A; Chen DD
    Bioanalysis; 2017 Feb; 9(3):313-326. PubMed ID: 28098491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
    Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
    Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
    J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Syringe Age Prior to Filling on Migration of Subvisible Silicone-Oil Particles into Drug Product.
    Song J; Hu G; Hamzaoui H; Krishnamachari Y; Persak SC; Xi H; Su Y
    J Pharm Sci; 2022 Dec; 111(12):3191-3194. PubMed ID: 36404459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions.
    Barnard JG; Rhyner MN; Carpenter JF
    J Pharm Sci; 2012 Jan; 101(1):140-53. PubMed ID: 22109687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
    Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
    J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Protein Aggregating Tungstates: Electrospray Mass Spectrometry Analysis of Extracts from Prefilled Syringes and from Tungsten Pins Used in the Manufacture of Syringes.
    Ronk M; Lee H; Fujimori K; Yeh P; Nashed-Samuel Y
    PDA J Pharm Sci Technol; 2016; 70(1):51-61. PubMed ID: 26797967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis.
    Zhang K; Wrzosek T; Desai KG; Monck M
    PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.
    Kalonia C; Kumru OS; Prajapati I; Mathaes R; Engert J; Zhou S; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):536-47. PubMed ID: 25302696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.